4dmedical Ltd. · ASX:4DX

4dmedical — Shareholder Meeting (October 2025)

34 slides from 4dmedical's shareholder meeting presentation, Oct 30, 2025

1. Slide 1: Presentation and Chair's address to the 2025 AGM

   ASX announcement ASX:4DX Presentation and Chair’s address to the 2025 Annual General Meeting 30 October 2025 4DMedical Limited (ASX: 4DX, “4DMedical” or the “Company”) attaches the following materials to be presented at the Annual General Meeting of Shareholders to be held today at 12:00pm AEDT: 1.

2. Slide 2: Chair's Address

   4DMedical Limited 2025 Annual General Meeting Chair’s Address 12:00pm, Thursday, 30 October 2025 Firstly, my thanks to you, our shareholders. We are grateful for your support and participation throughout the year, including the recent exercise of $22.6m of quoted options at almost 100% take-up. I al

3. Slide 3: Chair's Address (continued)

   U.S. reimbursement for CT:VQ™ is a pivotal milestone making the product more readily accessible across over 4,000 Medicare-certified hospitals in the U.S. This benchmark also provides a solid reference point for private payers. The Board is delighted with the pace of FDA clearance and U.S. reimbursem

4. Slide 4: Leading Cardiopulmonary Imaging into the Next Era

   4DMedical Limited (ASX:4DX) Annual General Meeting 30 October 2025 Leading For personal use only Cardiopulmonary Imaging into the Next Era Copyright © 4DMedical Limited 2025 Level 7, Melbourne Connect 700 Swanston Street Melbourne, Victoria 3053 Australia ABN 31 161 684 831 www.4dmedical.com

5. Slide 5: Disclaimer

   Disclaimer This presentation has been prepared by 4DMedical Limited (ACN 161 684 831) (Company or 4DMedical). This presentation contains summary information about the Company, its For personal use only subsidiaries and the entities, businesses and assets they own and operate (Group) and their activi

6. Slide 6: Agenda

   Agenda 1. Opening & introductions For personal use only 2. Chair’s address 3. CEO’s address 4. Procedural matters 5. Formal business 6. Closing remarks 3 4DMedical Limited (ASX:4DX) October 2025

7. Slide 7: Board of Directors

   Board of Directors – significant medical and commercial sector experience LIL BIANCHI Dr GERALDINE McGINTY MD For personal use only Non-Executive Chair Non-Executive Director Chair, Audit & Risk Committee Internationally recognised expert in health care strategy and imaging Experienced contributor o

8. Slide 8: Chair's address

   Chair’s address Lil Bianchi For personal use only Non-Executive Chair 5

9. Slide 9: CEO's address

   CEO’s address Dr Andreas Fouras PhD For personal use only Managing Director & CEO 6

10. Slide 10: Who is 4DMedical

    Who is For personal use only The leading pulmonary & • Structural & Functional Imaging software cardiothoracic imaging software company in the market • 100+ patented technologies • 9 FDA cleared devices 4DMedical was founded in Melbourne in 2013 to bring breakthrough lung function imaging • 130 glob

11. Slide 11: Portfolio

    Portfolio Pulmonary Function Pulmonary Structure Cardiovascular For personal use only XV LVAS® FDA Lung Density FDA/CE CAC FDA/CE Dynamic Ventilation Analysis (Fluoro) Emphysema, HAA, Fissures Coronary Calcification CT LVAS FDA Lung Texture CE PHA FDA/CE CT-based Ventilation Analysis ILD’s / Fibrosi

12. Slide 12: CT:VQ All the CONTRAST. None of the INJECTIONS.

    CT:VQ All the CONTRAST. None of the INJECTIONS. Value-adding the standard-of-care Chest CTs with Non-contrast functional imaging For personal use only CT:VQ Non-contrast Ventilation & Perfusion Routine CT Clinical Value 9 4DMedical Limited (ASX:4DX) October 2025

13. Slide 13: CT:VQ FDA Clearance

    CT:VQ FDA Clearance  Transformational Milestone - CT:VQ becomes the world’s first and only non-contrast, CT-based For personal use only ventilation-perfusion imaging technology to receive FDA 510(k) clearance.  Large Addressable Market - Over 1M VQ scans annually in the U.S.; USD $1.1B+ U.S. marke

14. Slide 14: Key commercial, product & clinical milestones: FY25 to date

    Key commercial, product & clinical milestones: FY25 to date FDA clearance for CT:VQ For personal use only • (U.S. Food and Drug Administration), the world’s first lung ventilation and prefusion software imaging tool, coupled with U.S. Reimbursement for CT:VQ from the U.S. Centers for Medicare and Me

15. Slide 15: Commercialisation Strategy

    Commercialisation Strategy US Government US Commercial Global Partnerships Australia For personal use only Enablers Olympus I-MED Exclusive Non-exclusive Integral Diagnostics AstraZeneca Reimbursement Nuance/Aidoc Jones, PRC, Spectrum Sector Veterans Affairs Community-based Clinics Global Pharma Com

16. Slide 16: SaaS revenue building momentum

    4DMedical SaaS revenue building momentum, driven by increased fundamentals of layering growth in site numbers and scan volume, throughout FY2025 Global sites delivering 4DMedical scans Structural & Functional Scan Analysis Group Operating Revenue For personal use only SaaS +60% +105% AUD $’000 Lease

17. Slide 17: Built the fundamentals, significant multipliers in play

    Built the fundamentals, significant multipliers in play during 2025 and beyond Foundations Multiplier #1 Multiplier #2 For personal use only ….2025 2026…. established Philips agreement CT:VQ displacing NUC:VQ  Commercialisation of comprehensive lung function portfolio established, with >$6m 25 x >$

18. Slide 18: Procedural matters

    For personal use only Procedural matters 15

19. Slide 19: Formal Business

    For personal use only Formal Business 16

20. Slide 20: Items of Business

    Items of Business Item 1: Financial Report, Directors’ Report and Auditors Report For personal use only Item 2: Remuneration Report Item 3: Spill Resolution Item 4: Re-election of Directors – Mr John Livingston and Mr Julian Sutton Item 5: Proposed issue of Equity Securities to Directors – Ms Lil Bi

21. Slide 21: Item 1: Financial Report, Directors' Report and Auditors Report

    Formal Business Item 1: Financial Report, Directors’ Report and Auditors Report For personal use only To receive and consider the Financial Report of the Company and its controlled entities and the Reports of the Directors and Auditor for the year ended 30 June 2025. 18 4DMedical Limited (ASX:4DX) O

22. Slide 22: Item 2: Remuneration report

    Formal Business Item 2: Remuneration report For personal use only To consider, and if thought fit, to pass, the following as an ordinary resolution: “That the Remuneration Report, as contained in the Directors’ Report for the year ended 30 June 2025, is adopted.” In Favour​ Against​ Proxy Discretion

23. Slide 23: Item 3: Spill Resolution

    Formal Business Item 3: Spill Resolution For personal use only To consider, and if thought fit, to pass, the following as an ordinary resolution: That, for the purposes of section 250V(1) of the Corporations Act and for all other purposes, approval is given for: (a) the Company to hold another meeti

24. Slide 24: Items 4A and 4B: Re-election of Directors

    Formal Business Items 4A and 4B: Re-election of Directors For personal use only Item 4A In Favour​ Against​ Proxy Discretion​ Abstain​ To consider, and if thought fit, to pass, the following as an ordinary resolution: 22,804,777 2,781,993 7,241,241​ 2,755,192 “That, for the purposes of clause 13.3(b

25. Slide 25: Items 5A to 5E: Proposed issue of Equity Securities to Directors

    Formal Business Items 5A to 5E: Proposed issue of Equity Securities to For personal use only Directors Item 5A In Favour​ Against​ Proxy Abstain​ To consider, and if thought fit, to pass, the following as an ordinary resolution: Discretion​ “That, for the purposes of Listing Rule 10.14 and for all o

26. Slide 26: Items 5A to 5E (continued)

    Formal Business Items 5A to 5E: Proposed issue of Equity Securities to For personal use only Directors (continued) Item 5D In Favour​ Against​ Proxy Abstain​ To consider, and if thought fit, to pass, the following as an ordinary resolution: Discretion​ “That, for the purposes of Listing Rule 10.14 a

27. Slide 27: Items 6A to 6E: Issue of securities in lieu of director fees

    Formal Business Items 6A to 6E: Approval for the proposed issue of For personal use only securities to Directors in lieu of base directors’ fees Item 6A In Favour​ Against​ Proxy Abstain​ To consider, and if thought fit, to pass, the following as an ordinary resolution: Discretion​ “That, for the pu

28. Slide 28: Items 6A to 6E (continued)

    Formal Business Items 6A to 6E: Approval for the proposed issue of For personal use only securities to Directors in lieu of base directors’ fees (continued) In Favour​ Against​ Proxy Abstain​ Item 6D Discretion​ To consider, and if thought fit, to pass, the following as an ordinary resolution: “That

29. Slide 29: Item 7: Grant of Options to the Managing Director and CEO

    Formal Business Item 7: Grant of Options to the Managing Director and CEO For personal use only To consider, and if thought fit, to pass, the following as an ordinary resolution: “That, for the purposes of Listing Rule 10.14, sections 200B and 200E of the Corporations Act and for all other purposes,

30. Slide 30: Item 8: Resolution withdrawn

    Formal Business Item 8: Resolution withdrawn For personal use only 27 4DMedical Limited (ASX:4DX) October 2025

31. Slide 31: Item 9: Tax-Exempt Employee Share Plan

    Formal Business Item 9: Approval in respect of the Tax-Exempt Employee Share Plan For personal use only To consider, and if thought fit, to pass, the following as an ordinary resolution: “That, for the purposes of Listing Rules 7.1 and 7.2 Exception 13 and for all other purposes, the rules of the 4D

32. Slide 32: Item 10: Renewal of Proportional Takeover Provisions

    Formal Business Item 10: Renewal of Proportional Takeover Provisions in Constitution For personal use only To consider, and if thought fit, to pass, the following as a special resolution: “That, for the purposes of section 648G(4)of the Corporations Act and for all other purposes, the Shareholders a

33. Slide 33: Poll

    For personal use only Poll 30

34. Slide 34: 4DMedical Limited Annual General Meeting October 2025

    For personal use only 4DMedical Limited (ASX:4DX) Annual General Meeting 30 October 2025 Copyright © 4DMedical Limited 2025 Level 7, Melbourne Connect 700 Swanston Street Melbourne, Victoria 3053 Australia www.4dmedical.com ABN 31 161 684 831

4DMedical — Shareholder Meeting (October 2025) on 6ix